Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

Abstract: A urinal assembly comprising a body comprising a bottom wall, front and back walls, first and second side walls bridging the front and back walls, an open mouth positioned generally opposite the bottom wall, and an attachment feature positioned proximate to the open mouth. The attachment feature includes outer and inner edges and an opening defined by the inner edge. The urinal assembly further comprises a lid including a lid portion and a strap having a fastener positioned at a distal end. The fastener includes a central portion positioned between first and second arms. Each of the first and second arms has a first end coupled to the central portion and a second end positioned a distance away from the central portion. The first and second arms extend through the opening such that the first and second free ends of the arms abut the inner edge of the attachment feature.